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Brain imaging studies have revealed that both the hippocampus and prefrontal cortex undergo selective volume reduction in major depressive disorder (MDD). One of the most consistent findings, associated with the volume reduction, in postmortem studies of MDD is a decrease in the density and number of glia, in several cortical areas (1) . The decreases in glial density are accompanied by a reduction of astrocytic markers, such as glial fibrillary acidic protein (GFAP) and glutamine synthetase (1, 2) , thus suggesting that glia, especially astrocytes might be involved in the pathophysiology of MDD.
One of the major role of astrocytes is the production of neurotrophic factors, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), fibroblast growth factor (FGF) and glial cell line-derived neurotrophic factor (GDNF), which support neurogenesis, gliogenesis, development, plasticity and survival (3) .
GDNF, a member of the transforming growth factor (TGF)- super family, was originally purified from a rat glial cell line supernatant as a trophic factor for midbrain dopamine neurons, and was later found to have pronounced effects on other neuronal populations and glia (4) . GDNF improves the cognitive function (5, 6) while also inhibiting drug-induced dependence (7) . These results suggest that GDNF plays a crucial role in not only neuronal development, but also neuronal and glial plasticity in higher-ordered brain function.
A growing body of evidence suggests that GDNF, as well as BDNF is involved in the pathophysiology of MDD (8) (9) (10) (11) (12) . GDNF has been shown to decrease in the peripheral blood of patients with MDD (8) . In addition, the decreased blood level of GDNF in MDD has been reported to increase after antidepressant treatment (13) . We have also previously shown that antidepressants increase the GDNF production in C6 glioma cells (C6 cells), rat astrocytes and normal human astrocytes (NHA) (14, 15) . Treatment with antidepressants alters the GDNF levels in rodents in vivo and glial cell culture in vitro (16) (17) (18) . These findings suggest that an increase of GDNF production may be involved in the therapeutic effect for MDD. Therefore, understanding of the mechanism of GDNF production in response to antidepressants in glial cells might thus provide some novel insights into the treatment of MDD (19) .
The monoamine-independent acute activation of protein tyrosine kinase (PTK), extracellular signal-regulated kinase (ERK) and cAMP responsive element binding protein (CREB) signaling cascade by antidepressants plays a crucial role in GDNF production in glial cells. In fact, amitriptyline treatment increases the phosphorylation of several phosphotyrosine-containing proteins (15) . Therefore, PTK seems to play an important role in GDNF production by antidepressants. However, the specific type of PTK involved the effect of antidepressants, and the mechanism of PTK activation by antidepressants remain unknown (15, 20) . This study attempts to clarify the type of PTK and elucidate its precise mechanism of GDNF production by antidepressants. goat), normal goat IgG, mouse IgG 1 isotype control (R&D Systems, Minneapolis, MN).
Cell culture
The cultures of C6 cells have been described previously (15) . In brief, C6 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 2 mM L-glutamine and 5% fetal bovine serum (Sigma-Aldrich Co.) in a 5% CO 2 humidified atmosphere. Normal human astrocytes (NHA), derived from fetal tissue (male, 18 weeks), were purchased from Cambrex (Walkersville, MD), and grown in ABM TM (Cambrex) in a 5% CO 2 humidified atmosphere. More than 80% of NHA expressed GFAP. For drug treatment, the medium was replaced with serum-free Opti-MEM (Invitrogen) containing 0.5% bovine serum albumin (Sigma-Aldrich Co.), and the cells were incubated for 24 h, and then the cells were treated with various drugs of interest.
Extracellular signal-regulated kinase (ERK) activity assay
The ERK activity assay has been described previously (15) . In brief, C6 cells were cultured at a density of 1.6 x 10 5 /cm 2 on a 6-well plate with 3 mL of growth medium. NHA were then cultured at a density of 0.8 x 10 5 /cm 2 on a 6-well plate with 2 mL of growth medium. After drug treatment, the cells were collected in a cell lysis buffer. The total amount of protein in each sample was adjusted to the same amount. The ERK activities were determined using an assay kit according to the manufacturer's instructions (Cell Signaling Technology, Beverly, MA).
Western blotting
Western blotting has been described previously (15, 21 
RNA interference
The transfection of small interfering RNA (siRNA) has been described previously (21) 
Real-time RT-PCR assay
The real-time RT-PCR assay has been described previously (15) . In brief, the first strand cDNA was synthesized from 500 ng of total RNA by using a RNA PCR Kit (AMV) Ver.3.0 (Takara Bio Inc., Ohtsu, Japan 
RESULTS

Effects of tyrosine kinase inhibitors on the amitriptyline-induced ERK activation.
Genistein, a general tyrosine kinase inhibitor, inhibited the amitriptyline-induced ERK activation and following GDNF production (15) . Actually, treatment with amitriptyline increased the phosphorylation levels of a number of phosphotyrosine containing proteins in C6 cells (15) . Selective inhibitors of tyrosine kinase were used to identify which types of PTK are involved in the effect of amitriptyline. SU5402 and PD173074 (FGFR inhibitors) completely inhibit the ERK activation induced by amitriptyline treatment in C6 cells. However, K252a [tropomyosin-related kinase (Trk) inhibitor] or AG1478 [epidermal growth factor receptor (EGFR) inhibitor] have no effect ( Fig  1A) . FGFR inhibitors alone have no effect on basal levels of ERK activity (21) . FGFR inhibitors, but not Trk or EGFR inhibitors, also selectively and completely block the amitriptyline-induced ERK activation in NHA (Fig 1B) .
Effects of FGFR1 or FGFR2 knock down on the amitriptyline-induced ERK activation.
The mammalian FGFR family consists of a group of four transmembrane proteins with intrinsic tyrosine kinase activity (FGFR1-FGFR4) (23) . C6 cells express FGFR1 (145 kDa: glycosylated mature type and 120 kDa: unglycosylated immature type) and FGFR2 (100 kDa) (21) . Therefore, the specific siRNAs were used for FGFR1 and 2 knock downs. The transfection of FGFR1 siRNA largely reduced the protein level of both 145 and 120 kDa of FGFR1 (20.2 ± 7.6%***, 21.6 ± 7.4%*** of basal, respectively, ***p<0.001). The transfection of FGFR2 siRNA significantly reduced the protein level of FGFR2 (61.5 ± 2.4%* of basal, *p<0.05). Control siRNA did not affect the expression levels of FGFR1 and FGFR2 for up to 100 nM at 48 h after transfection (FGFR1 145 kDa, 114.7 ± 4.5%; FGFR1 120 kDa, 112.6 ± 2.4%; FGFR2 100.9 ± 13.2% of basal, respectively) (Fig 1C) . We also confirmed that siRNA for individual FGFR caused similar reductions at the mRNA level (FGFR1 mRNA, 59.0 ± 10.0%**; FGFR2 mRNA, 77.6 ± 8.2%* of basal, respectively, *p<0.05, **p<0.01). The amitriptyline-induced ERK activation was significantly blocked by either FGFR1 siRNA or FGFR2 siRNA transfection, while control siRNA had no affect up to 100 nM (Fig 1D) . The knockdown of FGFR1 is much more effective, but only partially decreases the ERK activation by amitriptyline, while the knockdown of FGFR2 completely blocks the activation of ERK, even though the protein is only reduced to 60% of the basal level. The transfection of FGFR1 siRNA increased FGFR2 mRNA expression (124.8 ± 8.1%* of basal, *p<0.05), while transfection of FGFR2 siRNA had no effect on FGFR1 mRNA expression (98.2 ± 12.9% of basal). The adverse effect of FGFR1 siRNA on FGFR2 expression may attenuate the effect of FGFR1 siRNA transfection on the ERK activation by amitriptyline. Amitriptyline treatment increased phosphorylation of FGFRs and FRS2.
The amitriptyline-induced ERK activation was inhibited by specific inhibitors or siRNA for FGFRs. These results suggest the possibility that amitriptyline treatment induces FGFRs activation. Therefore, the effect of amitriptyline on FGFRs phosphorylation was examined by using phospho-FGFR (Tyr653/654) antibody, which recognizes phosphorylated FGFR1 (145 and 120 kDa), and FGFR2 (100 kDa) (21) . The phosphorylation level of all FGFR subtypes significantly increased after 5 min of amitriptyline treatment. The levels of total FGFRs did not change following 60 min of amitriptyline treatment (Fig 2A) .
Experiments
confirmed that amitriptyline treatment increased FGFR phosphorylation. However, the level of FGFR phosphorylation by amitriptyline (25 M) treatment was relatively low (about 1.5-fold increase) in comparison to the level induced by FGF-2 (10 ng/ml) treatment (about 4-fold increase) (21) , and the standard deviation was high. Therefore, due to the sensitivity of the antibody, it was difficult to characterize the amitriptyline-induced FGFR phosphorylation in detail. Therefore, the effect of amitriptyline on FGFR substrate 2 (FRS2), which is a member of FRS family of lipid-anchored docking protein was examined as an alternative index of FGFR activation. FRS2 is the primary substrate for the FGFR kinase and links the FGFR and their Ras/MAP kinase signaling cascades (24, 25) . A valine-threonine motif encoded by alternatively spliced sequences in the intracellular juxtamembrane domain of FGFR1 and FGFR2 is important for association with FRS2 (26, 27) . The phosphorylation of FRS2 induced by amitriptyline treatment significantly increased after 5 min of treatment, as well as FGFRs phosphorylation, and sustained an increase at 60 min in C6 cells. The amount of total FRS2 did not change following 60 min of amitriptyline treatment (Fig 2B) .
FRS2 also plays role in mediating the intracellular signals that are generated at the cell surface by activation of the NGF or EGF receptors (27, 28) . The effects of inhibitors for FGFR, Trk or EGFR were examined to confirm whether the amitriptyline-induced FRS2 phosphorylation is selectively mediated by FGFRs. As expected, the amitriptyline or FGF-2-induced FRS2 phosphorylation was selectively inhibited by SU5402 and PD173074 (FGFR inhibitors) in C6 cells. However, K252a (Trk inhibitor) or AG1478 (EGFR inhibitor) did not have any effect (data not shown). These results confirmed that FRS2 phosphorylation selectively indicated the activation of FGFR.
NHA express FGF-2 and FGFR (29 Table 1) . Effects of FGFR inhibitors on CREB phosphorylation and GDNF production induced by amitriptyline treatment.
Antidepressants increase CREB phosphorylation and CRE-mediated GDNF mRNA expression in glial cells (20) . The effects of FGFR inhibitors on the amitriptyline-induced CREB phosphorylation and GDNF production were examined. SU5402 and PD173074 significantly inhibited CREB phosphorylation, GDNF mRNA expression and GDNF release induced by amitriptyline treatment (Fig 3) . There was no effect on the basal level of CREB phosphorylation (SU5402 only, 42.6 ± 7.89%; PD173074 only, 49.0 ± 5.97% of control) and GDNF release (SU5402 only, 28.6 ± 8.9 pg/mL; PD173074 only, 3.7 ± 3.2 pg/mL) by inhibitors alone. A previous study confirmed that there was no effect on basal levels of GDNF mRNA by FGFR inhibitors alone (21) .
Effects of heparin on the amitriptyline or 5-HT-induced ERK activation.
The results suggest that antidepressants acutely activate FGFRs and the subsequent intracellular signaling molecules (FRS2, ERK and CREB), and increase GDNF production. 5-HT increases GDNF production through 5-HT 2 receptor-mediated FGFR2 transactivation, which does not involve FGFR ligands (21) . We next attempted to elucidate whether the activation of FGFR signaling by amitriptyline is associated with FGFR ligands or not. The effect of heparin, a chelator of FGFR ligands that blocks binding of FGFR ligands to cell surface receptors, was examined (30, 31) . We used the ERK activity as an index of FGFR activation to characterize the mechanism, because ERK is most sensitive among FGFR related intracellular signaling molecules. The amitriptyline-induced ERK activation was dose-dependently and completely inhibited by heparin in C6 cells, while the 5-HT-induced ERK activation was not affected by heparin ( Table 2) . There was no effect on the basal levels of ERK activation by heparin (100 g/mL) alone (19.2 ± 7.89% of control). Heparin also blocked the amitriptyline-induced ERK activation in NHA ( Table 2) . These results suggest that the heparin-binding FGFR ligands are involved in the effect of amitriptyline. The mechanism of amitriptyline-induced FGFR activation thus seems to differ from that of 5-HT due to the involvement of the FGFR ligands. Effects of neutralize antibodies for FGFR ligands on the amitriptyline-induced ERK activation.
The effect of specific non-permeant neutralizing antibodies for FGFR ligands was examined to clarify which kinds of FGFR ligands contribute to the effect of amitriptyline. C6 cells were pretreated with FGF-1 neutralizing antibody (FGF-1 nAb) Both FGF-2 nAbs significantly inhibited ERK activation by amitriptyline, whereas FGF-1 nAb and negative control IgG had no effect ( Table 3) . In NHA, FGF-2 nAb (polyclonal) also significantly inhibited ERK activation by the amitriptyline treatment (Table 3) . Amitriptyline, but not 5-HT treatment, increases FGF-2 shedding in C6 cells. We next measured the levels of FGF-2 in the media using a very sensitive FGF-2 ELISA kit. Acute amitriptyline treatment (2 min) dose-dependently and significantly increased the level of FGF-2 in the media, although the increase in the FGF-2 level was small. In contrast, 5-HT treatment did not affect the level of FGF-2 in the media at all ( Table 4) . We tried to increase the sensitivity of FGF-2 detection in the media by combining a FGFR1 antibody and FGFR inhibitors that block the receptor mediated internalization of FGF-2; however, no improvement was observed. The effect of heparin and the neutralizing antibodies demonstrate that the shedding of FGF-2, at least in part, might be involved in the effect of amitriptyline. Effects of MMP inhibitors or Na/K-ATPase inhibitor on the amitriptyline-induced ERK activation.
Unlike many other growth factors, FGF-2 lacks a classic peptide sequence for its secretion, and the mechanisms for its release remain controversial. Therefore, different mechanisms for FGF-2 release have been proposed, including mechanical strain, membrane disruption, Na/K-ATPase and protease (32, 33) . As a result of lactate dehydrogenase (LDH) assay, amitriptyline treatment does not induce nonspecific protein release due to cell damage (15) . Matrix metalloproteinases (MMP) are involved in the shedding of plasma membrane-bound FGF-2 from its membrane anchor (34, 35) . Therefore, cells were pretreated with Na/K-ATPase inhibitor (ouabine), or broad-spectrum inhibitors of MMP (o-phenanthroline, phosphoramidon and GM6001) before treatment with amitriptyline. The amitriptyline-induced ERK activation was significantly reduced by MMP inhibitors, while Na/K-ATPase inhibitor or GM6001 negative control did not have effect in C6 cells (Fig 4A) . There was no effect on basal levels of ERK by inhibitors alone (o-phenanthroline, 21.3 ± 5.54%; phosphoramidon, 67.7 ± 9.38%; GM6001, 20.4 ± 7.47% of control, respectively 
Effects of MMP inhibitors on the 5-HT or FGF-2-induced ERK activation.
Treatment with amitriptyline seems to activate MMPs in glial cells. The effect of MMP inhibitors (GM6001 and o-phenanthroline) on the 5-HT or FGF-2-induced ERK activation was examined to determine whether MMP activation by amitriptyline occurred before or after FGFR activation. The 5-HT or FGF-2-induced ERK activation was not inhibited by MMP inhibitors (Fig 4BC) . In addition, the amitriptyline-induced FRS2 phosphorylation was inhibited by MMP inhibitors; while the FGF-2-induced FRS2 phosphorylation was not affected by MMP inhibitors (data not shown). These results suggest that the involvement of MMP activation by amitriptyline occur upstream of FGFR activation (Fig 6) .
Effects of MMP inhibitor on GDNF production induced by amitriptyline treatment.
The effects of GM6001 or GM6001 negative control on GDNF release by amitriptyline treatment were investigated. GM6001, but not GM6001 negative control, significantly inhibited the GDNF release induced by amitriptyline treatment (Fig 5) . There was no effect on the basal level of GDNF release by inhibitor alone (GM6001, 33.0 ± 9.46 pg/mL).
DISCUSSION
The present study demonstrated that antidepressants used in this study acutely activate the FGFR/FRS2/ERK/CREB signaling cascade through a monoamine-independent mechanism, finally resulting in GDNF production. The most significant finding of this study concerns the key role of FGFR on GDNF production by antidepressants. The amitriptyline-induced FGFR activation might be induced by MMP-dependent mobilization of FGFR ligands, such as FGF-2 from membrane store. The same signaling components (MMP, FGF-2, FGFR and FRS2) in C6 cells were identified to mediate the effect of amitriptyline on ERK in NHA. In addition, different types of antidepressants, but not non-antidepressants, commonly increased FRS2 phosphorylation, as well as GDNF release. These results provide the first evidence for FGFR activation by antidepressants in glial cells.
The experiment with siRNAs for FGFR suggests that the effect of amitriptyline occurred through both of FGFR1 and FGFR2. In accordance with the data of siRNA (Fig 1D) , amitriptyline increased both of FGFR1 and FGFR2 phosphorylation. However, the current data suggest that FGFR1 and FGFR2 differently participate in the effect of amitriptyline. There are two mechanisms for the difference in the contribution of FGFR1 and FGFR2 on the effect of amitriptyline. (1) The increase in the FGFR2 expression following FGFR1 siRNA transfection may attenuate the effect of FGFR1 siRNA. This result suggests that FGFR2 might play a role that is complementary to FGFR1. FGFR hetero-dimerization as well as homo-dimerization is required for signal transduction (32) . Therefore, the interaction between FGFR1 and FGFR2 seems to be important in the effect of amitriptyline. (2) The other FGFR ligands, with have high affinity for FGFR2, might be involved in the effect of amitriptyline. For example, FGF-9 has a high affinity for FGFR2 rather than FGFR1 (32) . Taken together, the interaction between FGFR1 and FGFR2 and the involvement of several FGFR ligands, contribute to the complexity in FGF signaling activated by amitriptyline treatment.
The current data showed that the amitriptyline-induced FGFR activation occurs by FGFR ligands, such as FGF-2. The effect of amitriptyline was completely inhibited by heparin, while it was partially inhibited by FGF-2 nAbs. The mammalian FGF family consists of 22 ligands that are distributed throughout the central nervous system. FGF-1 and FGF-2 are expressed in C6 cells and NHA (29, 36, 37) . FGF-9 has been detected in glial cells (38) , and increases the GDNF expression in C6 cells (39) . These results suggest that not only FGF-2, but also other heparin-sensitive ligands, such as FGF-9, might thus be involved in the effects of amitriptyline. The FGFR ligands accumulated on cell surface heparin sulfate proteoglycans (HSPG) seem to play an important role in the effect of amitriptyline, because heparin and neutralizing antibodies trap FGFR ligands on the outside of cell membrane (40) . The level of FGF-2 in the media was barely detected even by the highly sensitive ELISA, and slightly but significantly increased after amitriptyline treatment. Although, the mechanisms for FGF-2 shedding remain controversial, MMP is important for the effect of amitriptyline. We examined whether MMP inhibitors block FGF-2 shedding by amitriptyline treatment, but the effects were unclear because the amount of FGF-2 shedding by amitriptyline was relatively small. However, the differential effect of MMP inhibitors on amitriptyline or FGF-2-induced ERK activation suggests that amitriptyline seems to activate FGFR through MMP activation (Figs 4A, 4C, 6 ). Furthermore, amitriptyline does not seem to bind directly to FGFR. Further studies investigating the over-expression of GFP tagged FGF-2 (41) may elucidate how antidepressant induces FGF-2 shedding clearly.
Although the data showed the involvement of MMP in the effect of amitriptyline, the specific type of MMP and the precise mechanism of MMP activation by amitriptyline remains unknown. MMPs are a family of zinc-dependent endopeptidases with 24 identified members (42). There are reports showing that C6 cells express MMP-2, -9, -13 and membrane-type1 MMP (43, 44) . GM6001 inhibits MMP-1, -2, -3, -8, and -9 (45). Therefore, MMP-2 or -9 might be involved the effect of amitriptyline. There are two reports of MMPs-dependent FGFR activation (34, 35) . The activation of -opioid receptor in C6 cells induces FGFR transactivation through o-phenanthroline and phosphoramidon-sensitive MMP (34) . The activation of EP3 subtype receptor by prostaglandin E 2 in microvascular endothelial cells induces the intracellular activation of c-Src, the activation of MMP (predominantly MMP2), which in turn causes the mobilization of membrane-anchored FGF-2, results in FGFR activation (35) . The activity of MMPs is regulated by Ca 2+ , PKC, Src, Pyk2 and GTP binding protein, depending on the cell type (46) . Ca 2+ , PKC and opioid receptors were not found to be involved in the mechanism of amitriptyline-induced ERK activation (15) (unpublished data). Therefore, the precise mechanism of MMPs activation by antidepressants is currently being investigated in detail.
Both amitriptyline-and 5-HT-induced GDNF production were inhibited by FGFR and MEK inhibitors. These results suggest that the amitriptyline and 5-HT signaling to ERK share certain features, but they seem to differ in the mechanism of FGFR activation. The current results showed that amitriptyline activates both of FGFR1 and FGFR2 through an extracellular pathway, with the mobilization of FGFR ligands from a membrane store by MMP. In contrast, 5-HT selectively activates FGFR2 through an intracellular pathway that is regulated by Src family tyrosine kinase and stabilized microtubules (21) . FGFR is at the point of convergence of these two pathways, and crucial for GDNF production. These differences in the mechanism of FGFR activation between amitriptyline and 5-HT confirmed that the effect of amitriptyline on ERK activation, following GDNF production, thus occurred through a monoamine-independent pathway (Fig 6) . It is noteworthy that the amitriptyline-induced actions occur independently of the actions of amitriptyline on serotonin reuptake transporter (SERT), because C6 cells lack SERT (47) . Perhaps more importantly, these data suggest multiple sites of action for amitriptyline (and perhaps other antidepressants). Amitriptyline, but no other antidepressants, interacts directly with both TrkA and TrkB receptors (48) . C6 cells express both TrkA and TrkB receptors (49); however, Trk inhibitor (K252a) had no effect on the amitriptyline-induced ERK activation in C6 cells and NHA (Figs 1A, 1B) . These results exclude the possibility of the involvement of Trk receptors in the effect of amitriptyline. Several different classes of antidepressants also increased GDNF production following the activation of FRS2/ERK/CREB signaling cascade, although these antidepressants differ in structure and have no information about a different common target other than monoamine transporters. Therefore, it is likely that several presynaptic and postsynaptic molecular cascades contribute to the antidepressant effect (50) and that the GDNF production following FGFR activation results from one of these pathways.
The involvement of the FGF system is beginning to emerge from clinical and basic research studies for MDD. The FGF family has been shown to be downregulated in the cortex and hippocampus in post-mortem studies of individuals with MDD (51,52). On the other hand, both acute and chronic administrations of FGFR ligands have antidepressant-like effects in animal models (53). The current study found that antidepressants acutely activate FGFR signaling, and subsequently FGFR is involved in GDNF production by antidepressant treatment in glial cells. There are reports showing that FGF-2 treatment increases GDNF production in glial cells (39, 54, 55) , which is consistent with the current findings. Therefore, antidepressants activate both the FGF and GDNF systems in glial cells and multiple neurotrophic/growth factor systems seem to be cooperatively involved in the therapeutic effect of antidepressants. Clarifying the monoamine-independent novel target of antidepressants in glial cells might therefore contribute to the development of more efficient treatment for MDD. 
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